Clovis Oncology | CLVS

Clovis Oncology Profile

  • Sector: Health Technology
  • Industry: Biotechnology
  • Employees: 429

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Clovis Oncology in the news

Services We Offer

Need a custom stock scraper? Want to do some machine learning? We are here to help! Reach out to us!

Machine Learning

Custom Scraper

Automation

Consulting